Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Non Operating Income (2019 - 2025)

Historic Non Operating Income for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to $1.0 million.

  • Benitec Biopharma's Non Operating Income rose 2427.54% to $1.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $3.8 million, marking a year-over-year increase of 42070.37%. This contributed to the annual value of $3.8 million for FY2025, which is 42070.37% up from last year.
  • Latest data reveals that Benitec Biopharma reported Non Operating Income of $1.0 million as of Q2 2025, which was up 2427.54% from $834000.0 recorded in Q1 2025.
  • Over the past 5 years, Benitec Biopharma's Non Operating Income peaked at $1.3 million during Q4 2024, and registered a low of -$513000.0 during Q3 2022.
  • Moreover, its 5-year median value for Non Operating Income was -$21000.0 (2021), whereas its average is $194055.6.
  • As far as peak fluctuations go, Benitec Biopharma's Non Operating Income tumbled by 138888.89% in 2021, and later soared by 132142.86% in 2022.
  • Over the past 5 years, Benitec Biopharma's Non Operating Income (Quarter) stood at $14000.0 in 2021, then surged by 1321.43% to $199000.0 in 2022, then crashed by 35.18% to $129000.0 in 2023, then surged by 871.32% to $1.3 million in 2024, then dropped by 17.88% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q2 2025, $834000.0 for Q1 2025, and $1.3 million during Q4 2024.